Physician profile
Sara Hopper
NPI 1972054807
$21,039.66
in general payments reported to CMS, 2019-2025
25 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,813 · 2022: $2,022 · 2023: $4,273 · 2024: $6,113 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,966 · Food and Beverage: $5,839 · Consulting Fee: $960 · Education: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,965.83 |
| Food and Beverage | $5,839.16 |
| Consulting Fee | $960.00 |
| Education | $438.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,977.26 | 2023-2025 | Spevigo |
| Janssen Biotech, INC. | $4,939.05 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,204.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $924.94 | 2021-2025 | Dupixent, Libtayo |
| Epi Health, LLC | $900.00 | 2022 | |
| Incyte Corporation | $738.88 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $697.33 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $575.17 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $510.38 | 2021-2024 | Targretin, Siliq, Duobrii |
| Sun Pharmaceutical Industries INC. | $483.40 | 2021-2025 | Ilumya |
| Pfizer INC. | $463.69 | 2021-2025 | |
| Ucb, INC. | $446.31 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $413.11 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $350.88 | 2021-2025 | |
| Amgen INC. | $265.05 | 2021-2025 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $236.60 | 2025 | Vtama, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $221.22 | 2021-2025 | Sotyktu |
| Lilly USA, LLC | $175.45 | 2021-2025 | Ebglyss |
| Vyne Pharmaceuticals INC. | $164.76 | 2021 | |
| Arcutis Biotherapeutics, INC. | $112.29 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $88.93 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $63.44 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $53.77 | 2023-2024 | Nuzyra |
| Journey Medical Corporation | $18.43 | 2023 | |
| Tactile Systems Technology INC | $14.51 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.